abrdn Life Sciences Investors (NYSE:HQL) to Issue Quarterly Dividend of $0.62

abrdn Life Sciences Investors (NYSE:HQL) declared a quarterly dividend on Tuesday, August 11th. Investors of record on Monday, August 24th will be given a dividend of 0.62 per share on Wednesday, September 30th. This represents a c) annualized dividend and a dividend yield of 11.7%. The ex-dividend date is Monday, August 24th.

abrdn Life Sciences Investors Trading Up 0.8%

NYSE:HQL traded up $0.16 during midday trading on Wednesday, reaching $21.26. 55,638 shares of the stock traded hands, compared to its average volume of 127,024. abrdn Life Sciences Investors has a 12-month low of $13.44 and a 12-month high of $21.32. The business has a 50-day moving average of $19.11 and a two-hundred day moving average of $17.81.

Institutional Trading of abrdn Life Sciences Investors

Several hedge funds and other institutional investors have recently made changes to their positions in the business. KPP Advisory Services LLC boosted its position in shares of abrdn Life Sciences Investors by 2.7% in the 2nd quarter. KPP Advisory Services LLC now owns 25,251 shares of the company’s stock worth $505,000 after purchasing an additional 660 shares in the last quarter. 180 Wealth Advisors LLC increased its position in abrdn Life Sciences Investors by 2.2% during the 2nd quarter. 180 Wealth Advisors LLC now owns 152,829 shares of the company’s stock valued at $3,058,000 after buying an additional 3,271 shares in the last quarter. NewEdge Advisors LLC increased its position in abrdn Life Sciences Investors by 17.6% during the 1st quarter. NewEdge Advisors LLC now owns 23,788 shares of the company’s stock valued at $387,000 after buying an additional 3,562 shares in the last quarter. WNY Asset Management LLC purchased a new stake in abrdn Life Sciences Investors in the first quarter valued at about $239,000. Finally, Bank of America Corp DE raised its stake in abrdn Life Sciences Investors by 8.6% in the first quarter. Bank of America Corp DE now owns 115,585 shares of the company’s stock valued at $1,881,000 after buying an additional 9,145 shares during the last quarter. Hedge funds and other institutional investors own 32.21% of the company’s stock.

About abrdn Life Sciences Investors

abrdn Life Sciences Investors (NYSE: HQL) is a closed-end management investment company that seeks capital appreciation through investment in the life sciences sector. Established in 1994, the trust focuses on equity and equity-related securities of companies engaged in biotechnology, pharmaceuticals, medical devices, diagnostics and related fields. Its closed-end structure allows portfolio managers to maintain a stable pool of capital, pursue long-term investment strategies and employ leverage when deemed appropriate.

The fund’s portfolio spans both public and private companies, with an emphasis on businesses driving innovation in drug development, gene therapy, precision medicine and healthcare technology.